Investigational drug · Phase 3
IO102-IO103
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Metastatic Melanoma, Unresectable Melanoma, Melanoma.
Phase 3Last checked: Nov 20, 2026Latest source record: Apr 8, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
7
Any phase or sponsor naming "IO102-IO103"
First trial start
2022
Apr 11, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IO102-IO103", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metastatic Melanoma
- Unresectable Melanoma
- Melanoma
- Squamous Cell Carcinoma of Head and Neck
- Lung Cancer Non Small Cell
- Head and Neck Squamous Cell Carcinoma
- Urothelial Carcinoma Bladder
Approved drugs for the same conditions: Melanoma · Bladder and urothelial cancer · Head and neck cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "IO102-IO103" as an intervention, largest first.
- IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)Pivotal-lookingActive, not recruiting
IO BiotechIndustry
NCT05155254 · 407 participants · Start May 17, 2022 · Primary completion May 30, 2025
Drug: IO102-IO103; Pembrolizumab · For: Metastatic Melanoma; Unresectable Melanoma
Sites: Orange City, Florida; Orlando, Florida; Buffalo, New York · 112 sites in all
IO BiotechIndustry
NCT05077709 · 63 participants · Start Apr 11, 2022 · Primary completion Nov 30, 2025
Drug: IO102-IO103 in combination with pembrolizumab · For: Lung Cancer Non Small Cell; Head and Neck Squamous Cell Carcinoma; Urothelial Carcinoma Bladder
Sites: Duarte, California; Sacramento, California; San Diego, California · 21 sites in all
IO BiotechIndustry
NCT05280314 · 60 participants (planned) · Start Dec 21, 2023 · Primary completion Apr 30, 2025
Drug: IO102-IO103; Pembrolizumab KEYTRUDA® · For: Melanoma; Squamous Cell Carcinoma of Head and Neck
Sites: New Haven, Connecticut; Boston, Massachusetts; Richmond, Virginia · 15 sites in all
Inge Marie SvaneAcademic, hospital or other
NCT03047928 · 48 participants · Start Feb 22, 2018 · Primary completion Dec 31, 2022
Drug: Nivolumab; PD-L1/IDO peptide vaccine · For: Metastatic Melanoma
Sites: Herlev, Denmark · 2 sites in all
- A Study of IO102/IO103, Nivolumab, and Relatlimab in People With MelanomaActive, not recruiting
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
NCT05912244 · 43 participants · Start Jun 9, 2023 · Primary completion Jun 9, 2027
Drug: IO102/IO103; Nivolumab-Relatlimab · For: Melanoma
Sites: Hartford, Connecticut; Basking Ridge, New Jersey; Middletown, New Jersey · 9 sites in all
Cliniques universitaires Saint-Luc- Université Catholique de LouvainAcademic, hospital or other
NCT04445064 · 17 participants · Start Aug 14, 2020 · Primary completion Jun 8, 2024
Drug: IO102; IO103 · For: Oropharynx Squamous Cell Carcinoma; Larynx Squamous Cell Carcinoma; Hypopharynx Squamous Cell Carcinoma and 1 more
Sites: Brussels, Belgium
- IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder CancerActive, not recruiting
University of California, DavisAcademic, hospital or other
NCT05843448 · 6 participants · Start Apr 19, 2023 · Primary completion Mar 9, 2026
Drug: PD-L1/IDO Peptide Vaccine; Pembrolizumab · For: High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma; Stage 0a Bladder Cancer AJCC v8; Stage 0is Bladder Cancer AJCC v8 and 1 more
Sites: Sacramento, California
Newest research
PubMed records naming it or its code names, newest first.
- IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma.
Hassel JC, Arance A, Carlino MS, et al. · Ann Oncol 2026
- YIA26-003: Characterizing the Peripheral T-Cell Repertoire in Patients With Unresectable Melanoma Treated With the IDO- and PD-L1 Targeted Peptide Vaccine IO102-IO103 and Nivolumab-Relatlimab Fixed-Dose Combination.
Smithy JW, Ciallella V, Thant C, et al. · J Natl Compr Canc Netw 2026
- A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.
Kjeldsen JW, Lorentzen CL, Martinenaite E, et al. · Nat Med 2021
Also in development for Metastatic Melanoma
- ONC-392Gotistobart, BNT316Phase 35 trials
OncoC4, Inc. · Non Small Cell Lung Cancer, Ovarian Cancer, Advanced Solid Tumor
- RO7247669Tobemstomig, RG6139Phase 26 trials
Roche (Genentech) · Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer
- IOV-3001Phase 21 trial
Iovance Biotherapeutics, Inc. · Unresectable Melanoma, Metastatic Melanoma, Ocular Melanoma
- IOV-4001Phase 21 trial
Iovance Biotherapeutics, Inc. · Unresectable Melanoma, Metastatic Melanoma, Stage III Non-small Cell Lung Cancer
- OBX-115Phase 21 trial
Obsidian Therapeutics, Inc. · Tumor Skin, Metastatic Melanoma, Melanoma
- ST101Phase 21 trial
Sapience Therapeutics · Glioblastoma, Melanoma Stage IV, Breast Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.